Newman M Yeilding from 129 Edgewood Rd, Ardmore, PA 19003

Method Of Treating Psoriasis With Increased Interval Dosing Of Anti-Il12/23 Antibody
view source
US Patent:

20180036379, Feb 8, 2018
Filed:

Mar 28, 2017
Appl. No.:

15/471790
Inventors:

- Horsham PA, US
Kamyar Farahi - Spring House PA, US
Newman Yeilding - Spring House PA, US
International Classification:

A61K 38/20
C07K 16/24
A61K 39/00
A61K 39/395
A01K 67/027
C07K 14/54
Abstract:

A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.

view source

Specialties:

Internal Medicine
Hematology
Medical Oncology
Hematology & Oncology

Education:

University of Alabama at Birmingham (1985)

Address:

Ardmore, PA 19003

License #:

MD038019E - Expired

Category:

Medicine

Type:

Medical Physician and Surgeon

License #:

MT014221T - Expired

Category:

Medicine

Type:

Graduate Medical Trainee

view source

share these important results from the Phase 3 UNITI-1 induction study, which complement Phase 3 results from the UNITI-2 study and further support regulatory applications submitted seeking approval of STELARA for the treatment of moderately to severely active Crohn's disease," said Newman Yeilding,
Date: Mar 18, 2016
Category: Health
Source: Google

The next step in 2 1/2 year old Charlie Brown's harness training is Gr...

Newman M Yeilding